Administration of Intravenous Vitamin C in Novel Coronavirus Infection and Decreased Oxygenation (AVoCaDO): A Phase I/II Safety, Tolerability, and Efficacy Clinical Trial

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Ascorbic acid (Primary)
Indications COVID 2019 infections; Hypoxia; Severe acute respiratory syndrome
Focus Adverse reactions
Acronyms AVoCaDO

21 Dec 2020 Status changed from active, no longer recruiting to completed.
17 Sep 2020 Planned End Date changed from 1 Oct 2020 to 15 Oct 2020.
17 Sep 2020 Planned primary completion date changed from 1 Sep 2020 to 18 Sep 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com